$ARWR It’s the inarguable news that matters. Not rumors, short sellers or naysayers. This company is beginning to mature. Fact remains that many do not have the mental facilities/acuity to simply stay the course when panic becomes wretchedly contagious.
@Mxa77tetha@LindseyGrahamSC Hardly humiliating us. That’s an uninformed overreaction. It’s a process and the only negotiating tactics they seemingly understand thus far are violence and military superiority. Trump is giving them ample opportunity to choose between certain destruction or capitulation.
Our CEO, Chris Anzalone, Ph.D., recently sat down with @LABJnews to discuss recent milestones—including our first-ever FDA approval last month— and the #RNAi platform behind our growing pipeline.
Read the full article: https://t.co/3wcBjEdmuE
✔️Important point & predicts the path $ARWR is following. Both CEO Chris Anzalone and VP/Investor Relations Vince Anzalone have stated, it’s a “Shots on goal” business. The FDA notices this success ratio, as well. ~It bodes well for the future of both $ALNY & $ARWR
@MarketTrendAdv That RNAI sentiment has been echoed for 10+ years. The wild card was early expectations. Buying $ARWR now remains a very strong bet. $ALNY is a very apt growth comparison re RNA Interference future projections . ~POC creates a radically different 🐂 market dynamic for Arrowhead.
@MookTrader $ARWR May/could be (❓) conservative if harkening back to the intoxicating adrenaline buzz days when $ARWR was frolicking in the $90’s ~on a wing and a prayer. ~Pre-drug approval & now concrete platform validation.
@BikeRieder $ARWR Give the Jeffries webcast a listen to have a better understanding of the likely (imo) impact that REDEMPLO®️will have on the elevated triglyceride patient population.
https://t.co/yrNdDGGHhW
@BikeRieder $ARWR Heathy volume of shares trading hands. Indicates institutional buyers clocking in (post comprehension) how broad utilization REDEMPLO® (plozasiran) (FDA’s) approval will impact the market for high triglycerides, i.e. ultimately a diverse grouping of applications.
I’ve had the pleasure to work with Arrowhead to get expanded access to Plozasiran. It’s been life changing for my patient, like a miracle drug. Maybe the most humbling experience I’ve had in medicine to see a drug quickly cure a previously intractable disease. Congratulations!
@AAGDhillon@TheJusticeDept You’re standing on a hill all by yourself, Gavin. California voters seek transparency first. You certainly shouldn’t fear election monitoring, you should embrace it. ~May the best man or woman (fairly) win…
Bonafide “STREET” cred is closely linked to FDA drug approval. Platform proof of concept will be greatly strengthened w/1st approved drug. Exceptional (recent) BP collaborations showcase demonstrable fundamental belief in $ARWR. ~Go big or go home, it’s always a personal choice…
$ARWR It’s the inarguable news that matters. Not rumors, short sellers or naysayers. This company is beginning to mature. Fact remains that many do not have the mental facilities/acuity to simply stay the course when panic becomes wretchedly contagious.
@thorku Cornerbacks and safeties must sometimes think the next time MaHomes pulls that chicken💩 he’s gotta get clocked. A little 70’s NFL retribution? It’s wearing thin, you can’t have it both ways and expect grown arse men to just stand idly by. ~Used to be the league of FAFO.
@TadMakowiecki Haven’t sold a share since my early investigations in 2013. ~Haven’t even been tempted. I’m an avid reader and remain an $ARWR Bull. I firmly believe that the long term Bull narrative is becoming increasingly easy to understand.
100% Tad, Tech & financing are locked & loaded…